Litcius/Paper detail

Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer

Samantha B. Kemp, Marina Pasca di Magliano, Howard C. Crawford

2021Cellular and Molecular Gastroenterology and Hepatology52 citationsDOIOpen Access PDF

Abstract

Pancreatic ductal adenocarcinoma (PDA), the most common pancreatic cancer, is a nearly universally lethal malignancy. PDA is characterized by extensive infiltration of immunosuppressive myeloid cells, including tumor-associated macrophages and myeloid-derived suppressor cells. Myeloid cells in the tumor microenvironment inhibit cytotoxic T-cell responses promoting carcinogenesis. Immune checkpoint therapy has not been effective in PDA, most likely because of this robust immune suppression, making it critical to elucidate mechanisms behind this phenomenon. Here, we review myeloid cell infiltration and cellular crosstalk in PDA progression and highlight current therapeutic approaches to target myeloid cell-driven immune suppression.

Topics & Concepts

MyeloidImmune systemPancreatic cancerCancer researchTumor microenvironmentCytotoxic T cellMyeloid-derived Suppressor CellCrosstalkMedicineImmunologyBiologyCancerSuppressorInternal medicineIn vitroBiochemistryOpticsPhysicsImmune cells in cancerPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer | Litcius